# Phase III ALTU-135 CP Safety Trial

> **NCT00500084** · PHASE3 · TERMINATED · sponsor: **Anthera Pharmaceuticals** · enrollment: 39 (actual)

## Conditions studied

- Exocrine Pancreatic Insufficiency

## Interventions

- **DRUG:** Liprotamase

## Key facts

- **NCT ID:** NCT00500084
- **Lead sponsor:** Anthera Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-12
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 39 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2014-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00500084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00500084, "Phase III ALTU-135 CP Safety Trial". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00500084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*